FDA vs USDA: Who Regulates Bio/Med Shipments

Key takeaways
FDA oversees human and veterinary drugs, biological products, medical devices and most foods, while USDA agencies such as APHIS and FSIS cover animal and plant health and most meat and poultry.
The two agencies split jurisdiction by product and risk, so one biomedical shipment can trigger FDA entry review and an APHIS permit at the same time.
APHIS Veterinary Services regulates organisms and vectors that can spread livestock or poultry disease, and its Center for Veterinary Biologics licenses and permits veterinary biologics.
Human pathogens and human diagnostic samples fall under the CDC Import Permit Program, not APHIS.
FDA review moves faster when entry data is complete and accurate, and a refused shipment must be exported or destroyed within 90 days of the refusal notice.
The short answer to FDA vs USDA in biomedical logistics is that they regulate different risks. The Food and Drug Administration (FDA) looks at whether drugs, biological products, medical devices and most foods are safe and lawfully marketed for people and animals. The U.S. Department of Agriculture (USDA), mainly through the Animal and Plant Health Inspection Service (APHIS), looks at whether a shipment could carry a disease or pest into American livestock, poultry or crops. Many lab and clinical shipments touch only one agency. Some touch both, and those are the ones that stall at the border when nobody planned for the second set of FDA and USDA regulations.
This guide explains the difference between FDA and USDA oversight, how the two agencies relate, which shipments need both, what APHIS controls in biomedical shipping, and how to keep FDA import entries moving. The agency pages cited here were checked in October 2026. Permit forms and procedures change, so confirm current requirements with the agency named in each section before you ship.
What is the difference between the FDA and the USDA?
The FDA regulates products by what they are and how they will be used: human and veterinary drugs, biological products, medical devices, most foods, cosmetics and radiation-emitting products. The USDA regulates agriculture, including animal and plant health through APHIS and most meat, poultry and egg products through the Food Safety and Inspection Service (FSIS). In shipping terms, the FDA asks whether a product is admissible, and APHIS asks whether a material is a biological risk to animals or plants.
FDA describes its mission as ensuring "the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices" on its What We Do page. For a biomedical shipper this covers finished drugs, investigational products, vaccines and other biologics for people, diagnostic test kits, implants, instruments and the components that go into them.
APHIS works from a different starting point. Under 9 CFR Part 122, organisms are defined as cultures or collections of organisms, or their derivatives, "which may introduce or disseminate any contagious or infectious disease of animals (including poultry)." Vectors include animals that have been inoculated with or exposed to such organisms. Neither definition depends on whether the material is a commercial product. A research culture with no market value can still need an APHIS permit.
The table summarizes how the main product groups in biomedical logistics are split.
Material or product | Primary agency | What the agency checks |
|---|---|---|
Human drugs and investigational drugs | FDA | Registration, listing, approval or IND status, labeling |
Human biologics such as vaccines and blood products | FDA | License or investigational status, manufacturer data |
Medical devices and diagnostic kits | FDA | Registration, listing, 510(k) or PMA where required |
Animal drugs | FDA | Approval status and labeling for veterinary use |
Veterinary biologics such as animal vaccines | USDA APHIS, Center for Veterinary Biologics | Import permit under 9 CFR Part 104 |
Animal pathogens, animal-derived cultures and exposed materials | USDA APHIS, Veterinary Services | Permit for organisms and vectors under 9 CFR Part 122 |
Plant pests, soil and plant material for research | USDA APHIS, Plant Protection and Quarantine | Organism or soil permit |
Human pathogens and infectious human samples | CDC | Import permit under 42 CFR 71.54 |
Most meat and poultry products | USDA FSIS | Inspection and labeling of amenable species |
The pattern is that the FDA follows the product and its intended use, while APHIS follows the biological origin and disease risk. That is why the same vial can be ordinary for one agency and controlled for the other.
What is the relationship between the FDA and the USDA?
The relationship between the FDA and the USDA is a division of labor set by separate federal laws, with shared boundaries rather than a chain of command. Neither agency reports to the other. Each enforces its own statutes, and where a product sits on a boundary, the regulations and interagency agreements decide who leads. An approval or permit from one agency does not satisfy the other.
Food is the clearest example of the split. FDA's page on FDA-regulated meats explains that USDA FSIS has primary responsibility for meat from the species listed in the Federal Meat Inspection Act and for poultry from domesticated birds, while FDA regulates game meats and products that contain 3% or less raw meat. Food and drug logistics teams that ship nutrition products, specialty foods or animal-derived ingredients often deal with both agencies for this reason.
In biomedical shipping the boundary appears in two places. The first is veterinary products. FDA regulates animal drugs, while APHIS licenses and permits veterinary biologics such as animal vaccines and diagnostic kits for animal diseases. The second is the biological origin of an FDA-regulated product. A human-use product made with animal-derived materials is still an FDA product, but the animal-derived input, or a research sample that contains it, may separately need APHIS review.
APHIS states this directly. Its organisms and vectors page says a Veterinary Services permit "does not supersede any other state or federal regulations" and that additional permits may be required. Read that as a rule for every boundary case: clearing one agency is never proof that the shipment is cleared.
Which shipments need both FDA and USDA clearance?
Shipments need both FDA and USDA clearance when an FDA-regulated product or sample also contains, or was exposed to, material that APHIS controls. Typical examples are reagents, cell cultures or research samples with animal-derived components, investigational products that ship with animal-origin materials, and veterinary products that combine a drug with a biologic. The FDA reviews the entry for admissibility, and APHIS decides whether the biological material needs a permit.
Common combinations in life science shipping include the following.
Cell cultures grown in animal-derived media or serum, imported for research that will support an FDA submission.
Diagnostic or research reagents that contain animal antibodies, enzymes or tissue extracts.
Samples from animal studies, such as tissue or blood from inoculated animals, which APHIS treats as possible vectors or organism derivatives.
Investigational drug or biologic shipments packed with animal-origin components or controls.
Products for animal health where the drug component falls under FDA and a biologic component falls under the APHIS Center for Veterinary Biologics.
A third agency often joins the list. Human pathogens and human diagnostic samples are not regulated by APHIS. APHIS points those shippers to the CDC Import Permit Program, which operates under 42 CFR 71.54 and covers infectious biological agents, infectious substances and vectors that can cause disease in humans. A shipment of human cells grown with animal-derived serum can therefore raise CDC, APHIS and FDA questions at the same time. Our guide to importing human-derived materials into the United States covers the CDC side in detail.
When you are unsure, write down three facts before contacting any agency: what the material is, what organism or animal it came from, and what it will be used for. Those three answers decide which agencies have a say.
What does USDA APHIS regulate in biomedical shipping?
In biomedical shipping, USDA APHIS regulates materials that could spread animal or plant disease. Its Veterinary Services unit permits organisms and vectors that may cause disease in livestock and poultry, including materials exposed to animals or animal products outside the United States. Its Center for Veterinary Biologics controls imported veterinary vaccines and diagnostics. Its Plant Protection and Quarantine unit permits plant pests and soil.
Organisms and vectors
The core rule sits in 9 CFR 122.2. No organisms or vectors may be imported into the United States, or moved between states, without a permit issued by the Secretary of Agriculture. The permittee must agree in writing to follow the safeguards APHIS sets for that material. APHIS asks applicants to file VS Form 16-3, and its page says the fastest route is the APHIS eFile system. Questions go to the address APHIS lists, apie@usda.gov. The permit is issued to the U.S. recipient, so the consignee, not the foreign sender, owns the application.
Veterinary biologics
Veterinary vaccines, antibodies and diagnostic kits for animal diseases are a separate APHIS program. Its veterinary biologics import page explains that imports are governed by 9 CFR Part 104 and require a permit for distribution and sale, research and evaluation, or transit shipment. Research and evaluation permits last one year and cannot be renewed, so labs that import every year must reapply. The distribution and sale permit can only be held by a U.S. permittee.
Plant material and soil
Labs working with plant pathogens, soil samples or plant tissue deal with APHIS Plant Protection and Quarantine rather than Veterinary Services. Permit types in that program differ by material and by what the lab will do with it, so confirm the correct permit with APHIS Plant Protection and Quarantine and describe the intended use precisely in the application.
A USDA APHIS import permit is one of several permits a biomedical importer may need. For the wider picture, including CDC, Fish and Wildlife and other agencies, see our guide to import permits for U.S. trade compliance and the glossary entry on animal specimen imports.
How do you stay compliant with FDA import rules?
You stay compliant with FDA import rules by filing complete and accurate entry data, making sure every manufacturer, importer and product record matches FDA's databases, holding product until FDA decides admissibility, and answering any detention notice within the stated deadline. FDA import compliance for biologics, drugs and devices follows the same core process, with extra data elements for specific product types.
The FDA import process page explains that entries are submitted to U.S. Customs and Border Protection (CBP), which passes FDA-regulated lines to FDA. Higher-risk products, and entries with incomplete or inaccurate information, are flagged for manual review. FDA also states that "imported items should not be distributed into commerce until FDA has determined admissibility." The practical FDA shipping requirements for an importer come down to the steps below.
Confirm the product's regulatory status before it ships. Drugs and biologics need the correct approval, license or investigational status, and devices need registration, listing and any required 510(k) or PMA.
Collect the entry data FDA's entry submission page lists, including product code, product description, country of production and the names and addresses of the manufacturer, shipper, importer and delivered-to party.
Give your filer the Affirmation of Compliance codes that apply, such as registration or listing numbers. They are mandatory only in some cases, but correct codes help FDA screen the entry.
Check that the APHIS or CDC permit, if needed, travels with the shipment and matches the description on the invoice.
Keep the product intact and undistributed until FDA releases it, and store it within its labeled temperature range while it waits.
If FDA issues a Notice of FDA Action detaining the product, respond on time with the evidence requested.
The deadlines after a detention are short. FDA's detention and hearing page says the Regulatory Procedures Manual allows 10 business days from the date of detention to present testimony, and the notice generally gives 20 calendar days to allow for weekends and mail. If FDA refuses admission, its import refusals page states that the shipment must be destroyed or exported under CBP and FDA supervision within 90 days of the refusal notice, and FDA cannot extend that period.
For devices, FDA's medical device import page notes that FDA checks whether the declared importer is registered, and that a device requiring a PMA or 510(k) without one is subject to refusal. For temperature-sensitive products, the storage conditions during a hold matter as much as the paperwork. Our explainer on FDA temperature monitoring rules covers what records to keep.
A practical compliance checklist for biomedical shippers
The checklist below works for most imports that might involve both agencies. It does not replace advice from the agency itself, but it catches the gaps that cause most holds.
Step | Question to answer | Who confirms it |
|---|---|---|
Identify the product | Is it a drug, biologic, device, food or research material? | Importer and regulatory team |
Trace the biological origin | Does it contain or touch animal, human or plant material? | Supplier and lab scientist |
Map the agencies | Which of FDA, APHIS, CDC or FSIS has jurisdiction? | Regulatory team, with the agency if unclear |
Secure permits | Is each permit issued to the U.S. recipient and still valid? | Permittee |
Prepare entry data | Do FDA product codes, firm names and registration numbers match? | Importer and licensed customs broker |
Align documents | Do invoice, permit and packing list describe the material the same way? | Shipper and broker |
Plan for holds | Where will the product sit, and at what temperature, if FDA or CBP examines it? | Logistics provider |
The step that fails most often is the third one. Teams that know their FDA status well sometimes never ask whether an animal-derived component brings APHIS into the picture. Our article on preventing customs delays in bio/med shipping covers the document problems that cause the rest.
Common mistakes in FDA and USDA compliance
A few errors appear again and again in biomedical shipments that cross both agencies.
Treating one approval as universal. An FDA-approved product can still carry an APHIS permit requirement for an animal-derived component, and an APHIS permit says nothing about FDA admissibility. Each agency must be satisfied on its own terms.
Vague descriptions. "Research samples" or "biological reagents" tells neither agency what the material is. Name the material, its source species, its form and its use, and use the same wording on the permit, invoice and FDA entry.
Applying too late. Permits must be issued before the shipment arrives. APHIS issues Veterinary Services permits to the recipient, so a foreign supplier cannot fix a missing permit from abroad.
Missing the detention clock. The response window after an FDA detention starts on the detention date, not the date the importer reads the notice. Assign one person to watch for FDA notices on every regulated entry.
How Mercury fits in
Mercury ships time- and temperature-sensitive materials for life science and healthcare companies, and its customs brokerage service files entries that carry FDA data. The importer remains responsible for product status and for obtaining APHIS or CDC permits, so the most useful thing you can bring to any shipment is a clear description of the material, its origin and its intended use. With those facts settled, the agency map in this guide shows who needs to see what before the shipment leaves the origin.



